Background Revolution of chemo-immunotherapy (CT-IO) in the first-line treatment of metastatic non-small-cell lung cancers (NSCLC) without actionable genomic alterations (AGAs) has dramatically improved prognosis, providing long response in a subset of patien…
Read Full ArticleThis article was originally published on Plos.org. Click the button above to read the complete article.
